- AMGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $395.0 million.
- AMGN has traded 60,949 shares today.
- AMGN is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMGN with the Ticky from Trade-Ideas. See the FREE profile for AMGN NOW at Trade-Ideas More details on AMGN: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. The stock currently has a dividend yield of 1.8%. AMGN has a PE ratio of 20.3. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold. The average volume for Amgen has been 2.9 million shares per day over the past 30 days. Amgen has a market cap of $100.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.28 and a short float of 1.3% with 3.27 days to cover. Shares are up 16.4% year-to-date as of the close of trading on Friday.
- Investors have apparently begun to recognize positive factors similar to those we have mentioned in this report, including earnings growth. This has helped drive up the company's shares by a sharp 26.64% over the past year, a rise that has exceeded that of the S&P 500 Index. Regarding the stock's future course, although almost any stock can fall in a broad market decline, AMGN should continue to move higher despite the fact that it has already enjoyed a very nice gain in the past year.
- AMGEN INC has improved earnings per share by 21.8% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, AMGEN INC increased its bottom line by earning $6.65 versus $5.51 in the prior year. This year, the market expects an improvement in earnings ($8.38 versus $6.65).
- The revenue growth significantly trails the industry average of 43.4%. Since the same quarter one year prior, revenues rose by 10.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
- Net operating cash flow has increased to $2,227.00 million or 39.18% when compared to the same quarter last year. Despite an increase in cash flow of 39.18%, AMGEN INC is still growing at a significantly lower rate than the industry average of 100.59%.
- You can view the full Amgen Ratings Report.